SAN FRANCISCO, July 21, 2025 (GLOBE NEWSWIRE) -- On May 6, 2025 investors in BellRing Brands, Inc. (NYSE: BRBR) saw the price of their shares decline about 19% after BellRing announced during its Q2 2025 earnings call that it anticipated Q3 2025 reduction in retailer inventory levels. This announcement has prompted national shareholders rights firm Hagens Berman to open an investigation into whether BellRing Brands may have violated the securities laws concerning the company’s sales practices. The firm urge ...

Core Viewpoint - RxSight, Inc. is under investigation for potential violations of federal securities laws following a significant decline in stock price due to revenue forecast cuts related to a slowdown in product utilization [1][4][5]. Company Overview - RxSight manufactures and sells light adjustable intraocular lenses used in cataract surgery, with its main product being the Light Adjustable Lens (LAL) that can be customized post-surgery through non-invasive light treatments [2]. Financial Performance - The company previously reported strong sales for LAL and Light Delivery Device (LDD), but began experiencing a slowdown in LAL utilization noted in 2024 [3]. - On April 3, 2025, RxSight cut its 2025 full-year revenue forecast, leading to a stock price drop of approximately 38%, from $26.12 to $16.21 per share [4]. - A further revenue forecast cut on July 8, 2025, resulted in another 38% decline in stock price, from $12.79 to $7.95 per share [5].

Core Viewpoint - BellRing Brands, Inc. is under investigation for potential violations of federal securities laws, with concerns regarding the sustainability of its sales growth driven by temporary trade inventory loading rather than genuine consumer demand [1][2]. Group 1: Company Overview - BellRing operates in the convenient nutrition category, primarily known for its brands Premier Protein and Dymatize, which offer ready-to-drink protein shakes and powders [2]. - The company reported that Premier Protein achieved an all-time high in household penetration, indicating strong demand [2]. Group 2: Sales Growth and Challenges - The sales growth during the relevant period may have been artificially inflated due to temporary trade inventory loading at key retailers, raising questions about sustainable demand [2]. - On May 5, 2025, BellRing disclosed that several key retailers had reduced their weeks of supply on hand, which would negatively impact growth in Q3 2025 [3]. - Following this announcement, BellRing's stock price dropped by $13.96, or over 18%, from $77.34 to $63.38 per share [3]. Group 3: Legal Implications - Investors in BellRing are encouraged to seek legal options due to the ongoing investigation and potential securities law violations [4]. - Bleichmar Fonti & Auld LLP, the law firm leading the investigation, has a strong track record in securities class actions and has recovered significant amounts for shareholders in past cases [5].

Core Viewpoint - The SEC is preparing to take enforcement actions against Faraday Future and its executives due to a three-year-long fraud investigation related to misleading statements made during the company's 2021 SPAC merger [1][2][3]. Group 1: SEC Investigation - The SEC has issued "Wells Notices" to Faraday Future's founder Jia Yueting and president Jerry Wang, indicating potential enforcement actions against them and two unnamed former employees [1][2]. - The investigation focuses on "purported false and misleading statements" regarding the company's merger with a SPAC in 2021, with possible outcomes including injunctions, civil penalties, and disgorgement [3][10]. - The SEC's investigation has been ongoing for three years, with the Los Angeles enforcement office leading the inquiry [10]. Group 2: Internal Company Issues - Following the SPAC merger, new board members raised concerns about misleading statements and the control exerted by Jia over the company, as well as financial transactions between the company and Jia's entities [6][9]. - An internal probe was launched, leading to Jia being sidelined and Wang resigning after refusing to cooperate; the findings were shared with the SEC [9][10]. - In 2022, board members faced pressure from FF Global, a major shareholder group connected to Jia, which resulted in threats and ultimately led to the resignation of the board members [11][12]. Group 3: Company Developments - Faraday Future delivered its first electric SUV to customers in 2023, although there are allegations from whistleblowers claiming that these sales are fake and misleading [12]. - Despite the ongoing investigation, Jia was reinstated as co-CEO in April 2023 [10][12].

Core Viewpoint - Johnson Fistel, PLLP is investigating RxSight, Inc. for potential violations of federal securities laws related to misleading statements and undisclosed material information to investors [1][3]. Company Overview - RxSight, Inc. is facing scrutiny regarding its business outlook and product adoption trends, particularly after reporting significant declines in Light Delivery Device (LDD) sales and total revenue for Q2 2025 [3]. Financial Performance - On July 9, 2025, RxSight released preliminary financial results indicating notable declines in LDD sales and usage of its light adjustable intraocular lenses (LALs) [3]. - The company revised its full-year 2025 revenue guidance downward by approximately $42.5 million at the midpoint, attributing this to "adoption challenges over the last few quarters" [3]. Legal Investigation - The investigation by Johnson Fistel focuses on whether RxSight misled investors about its financial performance and future prospects [3]. - Investors who purchased RxSight securities and incurred losses may be eligible to participate in the investigation [2]. Whistleblower Information - Individuals with nonpublic information about RxSight are encouraged to assist with the investigation or explore options under the SEC Whistleblower Program, which may offer rewards of up to 30% of any successful enforcement action [4]. Law Firm Background - Johnson Fistel, PLLP is a nationally recognized law firm specializing in shareholder rights and securities fraud, with a strong track record in securing recoveries for clients [5][6].

Core Viewpoint - Kaskela Law LLC is investigating Solid Biosciences Inc. due to a significant decline in its stock price, which has dropped over 40% since September 2024 [1][2]. Group 1: Stock Performance - Solid Biosciences' stock price has decreased from over $10.00 per share to less than $6.00 per share, representing a decline of over 40% [1]. Group 2: Legal Investigation - The investigation aims to determine if Solid Biosciences and its officers and directors violated securities laws or breached fiduciary duties related to recent corporate actions [2].

Core Viewpoint - Kaskela Law LLC is investigating First American Financial Corp. on behalf of long-term investors due to a significant decline in the company's stock price since November 2024, which has dropped over 11% from above $70.00 to under $62.00 per share [1][2]. Group 1 - The investigation aims to determine if First American and its officers and directors violated securities laws or breached fiduciary duties related to recent corporate actions [2]. - The decline in stock price indicates potential concerns among investors regarding the company's governance and operational decisions [1][2]. Group 2 - First American shareholders are encouraged to reach out to Kaskela Law LLC for more information regarding their legal rights and options related to the investigation [3]. - Kaskela Law LLC specializes in representing investors in securities fraud, corporate governance, and merger & acquisition litigation on a contingent basis [3].

Group 1 - Halper Sadeh LLC is investigating CARGO Therapeutics, Inc. for potential violations of federal securities laws related to its sale to Concentra Biosciences, LLC, which is proposed at $4.379 in cash per share plus a contingent value right [1] - WNS (Holdings) Limited is also under investigation for its sale to Capgemini at $76.50 per share [2] - The firm may seek increased consideration for shareholders and additional disclosures regarding the proposed transactions [3] Group 2 - Shareholders are encouraged to contact Halper Sadeh LLC to discuss their legal rights and options without any out-of-pocket payment for legal fees [4] - Halper Sadeh LLC represents investors globally who have experienced securities fraud and corporate misconduct, recovering millions for defrauded investors [4]

Core Viewpoint - Centene Corporation is under investigation for potential violations of federal securities laws due to allegations of providing misleading business information, which has led to significant stock price decline following the withdrawal of its earnings guidance [1][4]. Company Overview - Centene is a managed healthcare company that specializes in government-sponsored programs such as Medicaid and Medicare, as well as health insurance plans on individual exchanges and commercial marketplaces [3]. Alleged Wrongdoing - On July 1, 2025, Centene announced its decision to withdraw its 2025 earnings guidance, citing declining market growth in 22 out of the 29 states it operates in. The company indicated that health risks in these states were much higher than previously anticipated in its risk adjustment calculations [4]. - Following this announcement, Centene's stock price dropped by $22.87 per share, representing a 40.37% decline, closing at $33.78 per share on July 2, 2025 [4].

Core Insights - BellRing Brands, Inc. is currently under investigation for potential violations of federal securities laws following a significant drop in stock price after a disappointing earnings call [1][2]. Group 1: Company Performance - During the second quarter 2025 earnings call, BellRing Brands reported that certain customers are optimizing their inventories, leading to a slowdown in sales growth projected for the third quarter to "low-single-digits" [2]. - Following this announcement, BellRing Brands' stock price fell nearly 19%, from $78.43 on May 5, 2025, to $63.55 on May 6, 2025 [2]. Group 2: Legal Investigation - Kessler Topaz Meltzer & Check, LLP is investigating potential securities law violations on behalf of BellRing Brands investors [1]. - The law firm has a history of prosecuting class actions related to securities fraud and has recovered billions for investors [3].